[Eculizumab as rescue therapy for lupus nephritis-related thrombotic microangiopathy].

G Ital Nefrol

UO Nefrologia, AOU Parma, Azienda Ospedaliera-Universitaria Parma, Dipartimento Medicina e Chirurgia, Università di Parma, Parma, Italy.

Published: June 2020

Thrombotic microangiopathy (TMA) is a frequent and severe complication in systemic lupus erythematosus (SLE). It is reported in almost 20-25% of renal biopsies of patients with lupus nephritis (LN) and is associated with a poor renal prognosis. We report the case of a patient suffering from an aggressive form of proliferative LN in association with thrombotic microangiopathy (TMA-LN), who was resistant to standard combined immunosuppressive treatment with corticosteroids and cyclophosphamide, as well as to plasma exchange (PEX). Eculizumab was given as a rescue therapy with an optimal clinical response. We performed a systematic review of the literature and identified 11 papers, published between 2011 and 2018, with a total of 20 patients, in which eculizumab was used, always as rescue therapy, to treat TMA-LN. All reported cases showed a positive clinical response to eculizumab with a high rate of remission. Even if sparse, available clinical cases and case series support the use of eculizumab in highly selected cases as rescue treatment for LN-TMA resistant to conventional combined immunosuppressive treatment.

Download full-text PDF

Source

Publication Analysis

Top Keywords

rescue therapy
12
thrombotic microangiopathy
8
combined immunosuppressive
8
immunosuppressive treatment
8
eculizumab rescue
8
clinical response
8
[eculizumab rescue
4
therapy lupus
4
lupus nephritis-related
4
nephritis-related thrombotic
4

Similar Publications

As the most prevalent subtype of lung cancer, lung adenocarcinoma (LUAD) is closely associated with angiogenesis, which is fundamental to its progression. ADAM8 (A disintegrin and metalloproteinase 8) is an enzyme associated with tumor invasion, while its implications in LUAD angiogenesis are a field that awaits exploration. A thorough investigation into the impacts of ADAM8 on LUAD angiogenesis could contribute to the development of therapeutic drugs for LUAD.

View Article and Find Full Text PDF

Background: Chemotherapy-induced nausea and/or vomiting (CINV) is an intractable adverse effect of anticancer drugs. Although prophylactic use of fosaprepitant may be effective in reducing CINV, there is a lack of studies evaluating the application of fosaprepitant in real world.

Aims And Methods: This study prospectively observed the effectiveness and safety for the prophylaxis of CINV in a real-world clinical setting.

View Article and Find Full Text PDF

The clinical value of short-term insemination: a retrospective analysis of 3496 patients.

BMC Pregnancy Childbirth

January 2025

Reproductive Obstetrics and Gynecology Center of the Second Affiliated Hospital, Nanjing Medical University, 210028, Nanjing, China.

Background: The safety and effectiveness of short-term insemination remain a subject of controversy. This study aims to investigate the impact of short-term insemination on both embryo quality and pregnancy outcomes and whether it is necessary to apply short-term insemination to all patients underwent in vitro fertilization (IVF).

Methods: A retrospective analysis was conducted on 3,496 patients from two centers over the period January 2016 to December 2022.

View Article and Find Full Text PDF

Although alveolar hyperoxia exacerbates lung injury, clinical studies have failed to demonstrate the beneficial effects of lowering the fraction of inspired oxygen (FO) in patients with acute respiratory distress syndrome (ARDS). Atelectasis, which is commonly observed in ARDS, not only leads to hypoxemia but also contributes to lung injury through hypoxia-induced alveolar tissue inflammation. Therefore, it is possible that excessively low FO may enhance hypoxia-induced inflammation in atelectasis, and raising FO to an appropriate level may be a reasonable strategy for its mitigation.

View Article and Find Full Text PDF

Orphan nuclear receptor NR2E3 is a new molecular vulnerability in solid tumors by activating p53.

Cell Death Dis

January 2025

Center for Precision Medicine Research, Marshfield Clinic Research Institute, Marshfield Clinic Health System, Marshfield, WI, USA.

The orphan nuclear receptor NR2E3 has emerged as a potential tumor suppressor, yet its precise mechanisms in tumorigenesis require further investigation. Here, we demonstrate that the full-length protein isoform of NR2E3 instead of its short isoform activates wild-type p53 and is capable of rescuing certain p53 mutations in various cancer cell lines. Importantly, we observe a higher frequency of NR2E3 mutations in three solid tumors compared to the reference population, highlighting its potential significance in tumorigenesis.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!